Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZR2 Followed by RDHAP in Initially Treated Mantle Cell Lymphoma
NCT05992597Phase 2Recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Aug 2022
- Primary completion
- Aug 2025
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
A Phase 2 trial of zanubrutinib in mantle cell lymphoma (MCL), sponsored by Zhejiang Cancer Hospital. Started Aug 2022; status: recruiting.
02
Drugs
zanubrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT05992597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05992597.